266
Participants
Start Date
February 4, 2021
Primary Completion Date
August 31, 2023
Study Completion Date
October 3, 2025
Nivolumab
Specified dose on specified days
Relatlimab
Specified dose on specified days
Local Institution - 0077, Hksar
Local Institution - 0079, Shatin
Local Institution - 0031, Taipei
Local Institution - 0032, Taoyuan District
Local Institution - 0034, Tainan City
Local Institution - 0003, Auckland
Local Institution - 0010, Ciudad de Buenos Aires
Local Institution - 0063, San Miguel de Tucumán
Local Institution - 0042, Taipei
Local Institution - 0020, Seongnam-si
Local Institution - 0073, Córdoba
Local Institution - 0050, Donostia / San Sebastian
Local Institution - 0090, Edirne
Local Institution - 0051, Madrid
Local Institution - 0049, Madrid
Local Institution - 0058, Pamplona
Local Institution - 0067, Pessac
Local Institution - 0105, Grenoble
Local Institution - 0041, Taichung
Local Institution - 0091, Kadiköy/Istanbul
Local Institution - 0047, Hradec Králové
Local Institution - 0069, Vandœuvre-lès-Nancy
Local Institution - 0048, Brno
Local Institution - 0106, Oaxaca City
Local Institution - 0074, Lyon
Local Institution - 0101, San Luis Potosí City
Local Institution - 0068, Clichy
Local Institution - 0113, Harbin
Local Institution - 0001, Singapore
Local Institution - 0107, Shanghai
Local Institution - 0038, Craiova
Local Institution - 0004, Singapore
Local Institution - 0117, Hangzhou
Local Institution - 0036, Cluj-Napoca
Local Institution - 0114, Changsha
Local Institution - 0118, Xi'an
Local Institution - 0108, Xi'an
Local Institution - 0070, Suceava
Local Institution - 0024, Temuco
Local Institution - 0018, Santiago
Local Institution - 0016, Barretos
Local Institution - 0019, Buenos Aires
Local Institution - 0017, Rosario
Local Institution - 0025, Belo Horizonte
Local Institution - 0060, Porto Alegre
Unidade de Pesquisa Clínica do Hospital da Clínicas de Ribeirão Preto-Clinical Oncology, Ribeirão Preto
Local Institution - 0015, São Paulo
Local Institution - 0029, Santiago
Local Institution - 0046, Prague
Local Institution - 0072, Matsuyama
Local Institution - 0054, Yokohama
Local Institution - 0076, Yokohama
Local Institution - 0045, Ōsaka-sayama
Local Institution - 0075, Ishikawa
Local Institution - 0071, Kyoto
Local Institution - 0100, Cuauhtémoc
Local Institution - 0013, Krakow
Local Institution - 0012, Bytom
Local Institution - 0009, Mysowice
Local Institution - 0039, Warsaw
Local Institution - 0037, Bucharest
Local Institution - 0011, Seoul
Local Institution - 0043, Seoul
Local Institution - 0066, Barcelona
Local Institution - 0089, Ankara
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY